Latest news with #radiopharmaceuticals
Yahoo
14 hours ago
- Business
- Yahoo
Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, 'Radiopharm' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Dr Oliver Sartor, MD to the Company's Scientific Advisory Board (SAB). Dr Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic, in Rochester, Minnesota. He was previously Laborde Professor of Medicine and Urology and Medical Director of Tulane Cancer Center in New Orleans under Tulane University School of Medicine. Dr Sartor has also held senior roles at LSU Health Sciences Center, Dana‑Farber/Harvard Medical School, and as Medical Oncology Co‑Chair of the GU Committee of NRG Oncology. Dr Sartor received his MD with honours from Tulane University School of Medicine in 1982, completed internal medicine residency at Tulane, and a medical oncology fellowship at the National Cancer Institute (NCI). Since 1990 he has focused on prostate cancer clinical research, authoring more than 500 peer‑reviewed publications and leading multiple pivotal Phase 3 trials that resulted in FDA approvals for therapies including samarium‑153 EDTMP, cabazitaxel, radium‑223, and PSMA‑targeted radioligand therapy. 'Dr Sartor brings an unparalleled depth of expertise in both clinical translation and radiopharmaceutical therapies,' said Riccardo Canevari, Managing Director and CEO of Radiopharm Theranostics. 'We're very honoured to welcome him to our SAB. His insight and leadership will be invaluable as we advance our radiopharmaceutical pipeline.' About Radiopharm Theranostics Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper. For more information: Investors:Riccardo CanevariCEO & Managing DirectorP: +1 862 309 0293E: rc@ Anne Marie Fields Precision AQ (Formerly Stern IR) E: Media:Matt WrightNWR CommunicationsP: +61 451 896 420E: matt@ Follow Radiopharm Theranostics: Website – Twitter – Linked In – –
Yahoo
11-07-2025
- Business
- Yahoo
Telix Pharmaceuticals (TLX) Announces That Gozellix® is Commercially Available
Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the The research firm stated that Telix Pharmaceuticals Limited (NASDAQ:TLX) is the most diversified, comprehensively positioned, and standalone publicly-traded radiopharmaceuticals company. The firm also cited the commercial-stage portfolio of targeted radiotherapy agents catering to the unmet needs in oncology. The company announced that its next-generation PSMA-PET imaging agent for prostate cancer, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), is commercially available nationally in the US. A robotic arm picking up a product assembly line, displaying the company's consumer healthcare and wellness offerings. Telix Pharmaceuticals Limited (NASDAQ:TLX) highlighted that Gozellix builds on proven diagnostic excellence to offer early and accurate detection of metastases at initial staging, with 90% specificity. Telix Pharmaceuticals Limited (NASDAQ:TLX) remains focused on innovation in PSMA imaging, and Gozellix was the result of this commitment. It provides a new level of flexibility in distribution, production, and scheduling, together with a high standard of service and reliability. Notably, PSMA-PET imaging has been established as the standard of care for staging and identifying biochemical recurrence of prostate cancer. That being said, only a relatively small fraction of 3.4 million men having prostate cancer in the US benefited, mainly due to access and availability challenges. Gozellix's enhanced formulation provides a greater level of patient access as well as convenience via an extended transportation distance and clinical administration window. Telix Pharmaceuticals Limited (NASDAQ:TLX)'s stock has a consensus price objective of $22.92. While we acknowledge the potential of TLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
10-07-2025
- Business
- Yahoo
Telix Pharmaceuticals (TLX) Announces That Gozellix® is Commercially Available
Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the The research firm stated that Telix Pharmaceuticals Limited (NASDAQ:TLX) is the most diversified, comprehensively positioned, and standalone publicly-traded radiopharmaceuticals company. The firm also cited the commercial-stage portfolio of targeted radiotherapy agents catering to the unmet needs in oncology. The company announced that its next-generation PSMA-PET imaging agent for prostate cancer, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), is commercially available nationally in the US. A robotic arm picking up a product assembly line, displaying the company's consumer healthcare and wellness offerings. Telix Pharmaceuticals Limited (NASDAQ:TLX) highlighted that Gozellix builds on proven diagnostic excellence to offer early and accurate detection of metastases at initial staging, with 90% specificity. Telix Pharmaceuticals Limited (NASDAQ:TLX) remains focused on innovation in PSMA imaging, and Gozellix was the result of this commitment. It provides a new level of flexibility in distribution, production, and scheduling, together with a high standard of service and reliability. Notably, PSMA-PET imaging has been established as the standard of care for staging and identifying biochemical recurrence of prostate cancer. That being said, only a relatively small fraction of 3.4 million men having prostate cancer in the US benefited, mainly due to access and availability challenges. Gozellix's enhanced formulation provides a greater level of patient access as well as convenience via an extended transportation distance and clinical administration window. Telix Pharmaceuticals Limited (NASDAQ:TLX)'s stock has a consensus price objective of $22.92. While we acknowledge the potential of TLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
09-07-2025
- Business
- Yahoo
Actithera draws new investors to radiopharma drug pitch
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Actithera, a radiopharmaceutical drugmaker based in Oslo, Norway and Cambridge, Massachusetts, has raised just under $76 million in Series A venture financing to build out its cancer drug pipeline. In a Wednesday statement, the biotechnology company said it would use the new funds to advance into clinical development an experimental treatment targeting what are known as fibroblast activation proteins. M Ventures, which helped found the company in 2021, co-led the Series A round with Hadean Ventures, Sofinnova Partners and 4BIO Capital. Five other firms also participated. Radiopharmaceuticals offer a better way to target tumor-killing radiation more precisely to cancerous cells and, accordingly, they've drawn rising interest from drugmakers. The technology works by attaching a radioisotope to a targeting compound via a specially engineered 'linker' molecule. While radiopharmaceuticals have been around for years — Bayer's Xofigo was approved in the U.S. in 2013 — the field has taken off since the success of Novartis' prostate cancer treatment Pluvicto. The drug earned Novartis more than $1.3 billion in 2025, giving the industry a glimpse of radiopharmaceuticals' sales potential. Other large companies, like Bristol Myers Squibb and Eli Lilly, have entered the field with acquisitions of earlier-stage public biotechs. Private radiopharma companies, meanwhile, drew more than $1.1 billion since 2022 from a group of 23 venture firms tracked by BioPharma Dive. Actithera is designing its cancer drugs so they can stay in a tumor for longer by binding tightly to proteins that help a tumor grow. Founded by Andreas Goutopoulos, a veteran of Merck KGaA's U.S. subsidiary EMD Serono Inc., the biotech is focused first on an enzyme called fibroblast activation protein, or FAP. The protein is expressed on cells that form connective tissue, but in cancer can support tumor growth. Actithera aims to eliminate those proteins and cancer-associated fibroblasts in 'a cross-fire effect that kills nearby tumor cells,' Goutopoulos said. 'It's a way to dismantle a critical barrier to immune and therapeutic access,' he wrote in an email to BioPharma Dive. Radiopharmaceuticals can be tricky to develop. Manufacturing is complex and expensive, and in response, companies like Novartis have opened dedicated production facilities. The isotope they contain also degrades over time, making the logistics of their delivery critical. Actithera is one of many up-and-coming biotechs looking to follow Novartis' lead. Some of those, including Novartis and Ratio Therapeutics, are also targeting FAP. Actithera has not disclosed which cancers it's targeting with its therapies. The company is 'preparing for clinical development in 2026' across multiple indications, Goutopoulos said. 'Actithera stands out as one of the most thoughtfully constructed radiopharma platforms we've seen, combining smart molecular design with a deep understanding of tumor biology and clinical need,' Roger Franklin, a partner at Hadean Ventures, said in a statement. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-07-2025
- Business
- Yahoo
4BIO Capital co-leads Actithera's oversubscribed $75.5 million Series A financing
4BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention Series A was co-led by 4BIO Capital, founding investor M Ventures, Hadean Ventures, and Sofinnova Partners, with syndicate including Bioqube Ventures, Surveyor Capital (a Citadel company) and others Proceeds will support clinical development of Actithera's fibroblast activation protein (FAP)-targeting candidate and pipeline expansion London, United Kingdom, 9 July 2025 – 4BIO Capital ('4BIO' or 'the Group'), an international venture capital firm unlocking the treatments of the future by investing in advanced therapies and other emerging technologies, today announces that it has co-led a $75.5 million Series A Financing round of Actithera (the 'Company'). Radiopharmaceutical therapy (or radioligand therapy, RLT) is a targeted form of radiotherapy that can treat cancers resistant to other therapies and represents a $7.5 billion market projected to grow to $14.4 billion by 20341. RLTs with the appropriate pharmacokinetic profile can achieve efficacy with minimal toxicity; however, attaining the ideal pharmacokinetic characteristics is not trivial. 4BIO's investment in Actithera highlights the clear need for a more systematic approach to optimizing RLT vectors and exemplifies the Group's strategy of identifying critical technology gaps, backing innovative solutions, and supporting them in high-growth markets. 4BIO co-led the oversubscribed round alongside founding investor M Ventures, Hadean Ventures, and Sofinnova Partners with additional participation from Bioqube Ventures, Innovestor's Life Science Fund, Investinor, Surveyor Capital (a Citadel company), and the second founding investor, Arkin Bio Ventures II. Therese Liechtenstein, incoming Board Member and Investment Director at 4BIO Capital, said: 'At 4BIO we invest in companies solving technical unmet needs to enable next-generation therapeutics. We are honoured to support Actithera, whose pipeline of molecules addresses key challenges in the nascent radioligand therapies space; a large therapeutic window through high tumour retention and low systemic exposure, applied to a lead programme that has significant pan-tumour therapeutic potential.' Dr Andreas Goutopoulous, Founder and CEO of Actithera, added: 'We are grateful for 4BIO Capital's support in this oversubscribed Series A, which is a strong validation of our approach. We set out to bring structure-based and kinetics-driven thinking from small molecule drug design into the world of radiopharmaceuticals. We engineer our radioconjugates for extended retention within tumours, making them ideally suited for longer-lived radionuclides and ultimately delivering more convenient dosing schedules and enhanced efficacy and safety for patients.' As part of the Series A financing, Therese Liechtenstein, Investment Director at 4BIO Capital will join the Actithera Board of Directors. The financing will support the advancement of Actithera's lead FAP asset into clinical development in multiple indications, while also enabling the continued development of its proprietary RLT discovery platform and preclinical pipeline. The Company's discovery platform combines rational drug design with radiochemistry to create novel small molecule radioligands that overcome current limitations in radiopharmaceutical development. Its three-pillar platform includes first-in-class covalent targeting strategies, designed to optimize tumour residence time, while ensuring rapid systemic clearance – improving precision, safety, and efficacy. Two additional proprietary approaches further support compound differentiation and improve tumour residence time and selectivity. This platform was validated through Actithera's work on FAP, a high-value theranostic target known for being difficult to drug with molecules that maintain prolonged tumour residency. These efforts have resulted in a FAP-directed RLT development candidate with best-in-class potential due to its optimal pharmacokinetic profile and tumour specificity. Dr Andreas Goutopoulos, founder and CEO, brings over 25 years of pharmaceutical and biotech industry experience, including a track record of more than a dozen development candidates. His background includes over a decade of discovery leadership at EMD Serono, where he led medicinal chemistry. In his role as Entrepreneur-in-Residence (EIR) at M Ventures, he led the scientific efforts of and supported a number of oncology small molecule biotechs. At Actithera, he is pioneering a chemistry-driven, precision approach to RLTs by integrating novel covalent-targeting chemistries, rational drug design principles and an isotope-agnostic philosophy. - End - Contacts 4BIO Capital +44 (0) 203 427 5500info@ ICR HealthcareAmber Fennell, Jonathan Edwards, Kris Lam +44 (0)20 3709 57004biocapital@ About 4BIO Capital4BIO Capital ('4BIO') is an international venture capital firm focused on investing in advanced therapies and emerging modalities, to unlock the treatments of the future. 4BIO's mission is to invest in, support, and grow early-stage companies solving technical bottlenecks that enable next generation therapeutics in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially transformative therapies for all patients. The 4BIO team comprises leading advanced therapy scientists and experienced life science investors with an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space. For more information, connect with us on LinkedIn and Twitter @4biocapital and visit About ActitheraActithera is a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs). Founded in 2021 by drug discovery innovator Dr. Andreas Goutopoulos, and seed investors M Ventures, and Arkin Bio-Holdings, Actithera applies various molecular design strategies, including covalent-targeting and an isotope-agnostic philosophy to invent RLTs with significant differentiation and larger therapeutic windows. Headquartered in Oslo, Norway, and Cambridge, Massachusetts, Actithera is committed to advancing a differentiated pipeline addressing critical unmet needs in oncology. Learn more at and on LinkedIn. 1 in to access your portfolio
